Sarepta Therapeutics Inc (LTS:0L35)
$ 121.67 0 (0%) Market Cap: 11.61 Bil Enterprise Value: 11.80 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 82/100

Sarepta Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 03:00PM GMT
Release Date Price: $91.87 (+11.16%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome, everyone, to the 39th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team.

The next presenting company is Sarepta. And speaking on behalf of the company, we have CEO, Doug Ingram. Before I turn it over to Doug, just wanted to highlight for those listeners on the webcast to please use the submit-a-question, ask-a-question button in the portal, and I'm happy to ask the question on your behalf. Doug, take it away.

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Thank you very much, Anupam. Let's pull the slide deck up now. Great. And good morning to everyone online, and thank you for joining us today. As a mission-driven leader in precision genetic medicine for rare disease with a pipeline of over 40 candidates across RNA and gene therapy and gene editing, there is much that we can discuss today.

However, in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot